Seri Yu, Shoda Hirofumi, Hanata Norio, Nagafuchi Yasuo, Sumitomo Shuji, Fujio Keishi, Yamamoto Kazuhiko
a Department of Allergy and Rheumatology , Graduate School of Medicine, the University of Tokyo , Tokyo , Japan.
Mod Rheumatol. 2017 Jul;27(4):696-698. doi: 10.3109/14397595.2015.1014153. Epub 2015 Mar 12.
A 59-year-old man who presented with continuous fever, livedo reticularis, and left leg ischemia with multiple tibial artery stenosis and renal artery aneurysm, as demonstrated by arteriography, was diagnosed with polyarteritis nodosa (PAN) 6 years ago. Although he frequently relapsed in spite of intensive immunosuppressive therapies, the disease activity of PAN was controlled with repeated rituximab (RTX) therapies and steroid doses were tapered safely. Peripheral CD19 B-cells disappeared soon after the 1st administration of RTX. Although CD19 B-cells remained absent, 3.1% of CD3CD20 T-cells were observed in the peripheral blood prior to the 2nd administration of RTX. Recent studies have suggested the pathogenic role of CD3CD20 T-cells in autoimmune diseases in the context of RTX therapy; therefore, their roles in the pathogenesis of PAN also need to be considered.
一名59岁男性,6年前被诊断为结节性多动脉炎(PAN),表现为持续发热、网状青斑以及左腿缺血,动脉造影显示多条胫动脉狭窄和肾动脉动脉瘤。尽管强化免疫抑制治疗后病情仍频繁复发,但通过重复使用利妥昔单抗(RTX)治疗,PAN的疾病活动得到控制,且类固醇剂量安全递减。首次给予RTX后外周血CD19 B细胞很快消失。虽然CD19 B细胞持续缺失,但在第二次给予RTX前外周血中观察到3.1%的CD3CD20 T细胞。最近的研究表明,在RTX治疗背景下,CD3CD20 T细胞在自身免疫性疾病中具有致病作用;因此,也需要考虑它们在PAN发病机制中的作用。